40
Participants
Start Date
May 31, 2002
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
Vinorelbine
20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
Capecitabine
825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
University of Washington; Seattle Cancer Care Alliance, Seattle
Collaborators (1)
Hoffmann-La Roche
INDUSTRY
Pfizer
INDUSTRY
University of Washington
OTHER